We are advancing a pipeline of novel therapeutics for autism, epilepsies, and other CNS disorders.


Pushing the boundaries of neuroscience drug discovery

We couple emerging advances in neuroscience drug discovery and precision medicine to develop our pipeline of small molecules for CNS disorders. Our approach aims at selectively inhibiting cation-chloride cotransporters, which are relevant to rescue atypical brain activity in neurological conditions.



Working at IAMA therapeutics

We are a team of scientists, researchers, and biotech industry experts who value excellence, innovation, integrity, equality, respect for diversity, and the sustainability of our future generations.

latest news

11 April 2024

IAMA Therapeutics Appoints Federico Bolognani as Chief Medical Officer

GENOA, Italy, April 11, 2024 — IAMA Therapeutics today announced the appointment of Federico Bolognani, MD, PhD, as Chief Medical Officer (CMO). Bringing extensive expertise in […]
19 February 2024

IAMA Therapeutics Successfully Dosed the First Two Cohorts in First-in-Human Clinical Trial

GENOA, Italy, February 19, 2024 — IAMA Therapeutics has successfully dosed the first two cohorts of subjects and has started dosing the third one in the […]
23 January 2024

IAMA Therapeutics Announces First Subject Dosed in Phase 1 Study of IAMA-6 for the Treatment of Autism and Epilepsy

GENOA, Italy, January 23, 2024 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain […]